Condition: Anaplastic Thyroid Cancer · Sponsor: Saint Petersburg State University, Russia
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer. Patients with anaplastic thyroid cancer who are treatment-naive (BRAF-negative) and who were previously treated with chemptherapy or targeted therapy are scheduled to undergo pembrolizumab and lenvatinib and evaluate the outcomes according to the primary and secondary endpoints.
This description comes directly from the study's public registry record.
Ilya Sleptsov, MD · +7(921)951-70-88 · newsurgery@yandex.ru
Ernest Dzhelialov · +7(911)134-50-44 · ernest.dzhelialov@gmail.com
Always discuss trial participation with your own doctor first.
| Saint Petersburg State University Hospital | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06374602